Closed · opens Mon 9:30 AM ET
The Marked Chart Wire · Health
Alexion Ultomiris
AstraZeneca unit Alexion received accelerated US approval for Ultomiris to treat IgA nephropathy in adults. The drug cut proteinuria by 43.4 percent versus placebo at 34 weeks in a Phase III trial.
Lung Cancer
Amgen reported that adding its medication to AstraZeneca’s immunotherapy reduced the chance of death by 58 percent for individuals with advanced lung tumors.
CRISPR Therapeutics
CRISPR Therapeutics' pipeline candidate CTX310 is viewed as having a larger market opportunity than its approved product Casgevy.
Nubeqa
Orion Corporation stated that adding Nubeqa to standard care significantly lowered the chance of disease spread or mortality in high-risk patients.
Cancer Vaccine
The two companies disclosed late-stage clinical findings for their mRNA therapy, intismeran autogene, after an information leak occurred.
AbbVie
The FDA approved an injectable version of AbbVie's Skyrizi to treat moderate to severe Crohn's disease.
Novartis
Novartis said its drug remibrutinib met primary endpoints in phase 3 trials for rhabdomyosarcoma. The treatment cut relapse rates by 35 percent compared with a rival therapy, and the company plans to seek global approval.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.